Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.
Aptose Biosciences Inc. Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies.
Aptose Biosciences Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.16. Operator: Good afternoon. My name is Hope, and I will be your conference operator today. I ...
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...
SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...
--Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its ...
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.
Aptose Biosciences Inc. 競合他社・同業他社分析 - Life Sciences セクター
Our AI model demonstrates 47% historical accuracy for APTO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.